Liver transplant patients over time experience an increasing trend toward colon cancer and non-Hodgkin lymphoma, according to an award-winning study led by a Loyola Medicine gastroenterologist. The study by Ayokunle Abegunde, MD, MSc, and colleagues also found that lung and heart transplant patients have a higher trend toward non-melanoma skin cancer. Dr. Abegunde was the senior author of the study, presented during the American College of Gastroenterology annual conference in Philadelphia.
Fixing or replacing faulty genes has emerged as a key to unlocking cures for numerous devastating diseases. But if the new, engineered genes can’t find their way into the patient’s genomic sequence, they won’t help. Johns Hopkins gastroenterologists Florin Selaru and Vivek Kumbhari believe they’ve taken a major step in the direction of helping patients with certain liver disorders by using an increasingly common endoscopic procedure to deliver therapeutic genes to the liver via
Kandice Fogle, 43, had just moved to Houston when she began experiencing pain in her back and groin. After undergoing a CT scan, doctors found a large mass in her liver. A biopsy confirmed that she had intrahepatic cholangiocarcinoma, more commonly known as bile duct cancer. After having the mass removed and undergoing chemotherapy and radiation treatment, her cancer returned six months later. Frightened that she would not live to
Research could uncover who is most at risk for nonalcoholic fatty liver disease and lead to new treatments for this increasingly common condition Nonalcoholic fatty liver disease, a condition where fat builds up in the liver, is now the most common chronic liver disease diagnosed in adults and children. Although the disease is linked with obesity, scientists don’t fully understand why some people develop it and others don’t. Findings from
Namodenoson, a Phase II drug developed by Can-Fite BioPharma Ltd. (NYSE MKT: CANF), has shown in newly published data that it prevents liver (hepatic) fibrosis progression in preclinical studies. "These latest study results add to the growing body of data that demonstrate Namodenoson's potential efficacy in combating non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH), indications for which there is currently no FDA approved drug. We are
There is no U.S. FDA approved therapy on the market today for Nonalcoholic steatohepatitis (NASH), a chronic liver disease found in adults and children. Between 5.6 and 8.4 million Americans are living with NASH today and this number is expected to jump to 25 million by 2025, driven by rising obesity rates. NAFLD, the liver disease which is a precursor to NASH, afflicts an estimated 30 million people today. These
Combining multiple non-invasive measures, researchers at University of California San Diego School of Medicine describe a novel method to quantify the progression of nonalcoholic fatty liver disease (NAFLD) to its more dangerous and deadly states — advanced fibrosis and cirrhosis. The findings are published in the Oct 5 online issue of Hepatology. Roughly one-quarter of all Americans — an estimated 100 million adults and children — have NAFLD, which occurs